[{"data":1,"prerenderedAt":289},["ShallowReactive",2],{"story-110814-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":55,"questions":56,"relatedArticles":78,"body_color":287,"card_color":288},"110814",null,"FDA Vaccine Approval Chaos Creates Compliance Uncertainty for Health Product Sellers","- Political pressure destabilizes regulatory standards, forcing health supplement and medical device sellers to reassess compliance timelines and market entry strategies across US and international markets",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,10,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,29,36,49,50,51,52,53,54,10],"https://images.mktw.net/im-59581976?width=1260&height=840","https://i.cbc.ca/ais/1.5847652,1608317719000/full/max/0/default.jpg?im=Crop%2Crect%3D%280%2C277%2C5366%2C3018%29%3B","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/shutterstock_2623556391-1-430x241.jpg","https://cdn.sanity.io/images/0vv8moc6/pharma_commerce/a685c1c8db0a3926de51672a887e5b64ea5f107c-1280x720.png","https://nypost.com/wp-content/uploads/sites/2/2026/02/121631495.jpg?quality=75&strip=all&w=1024","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/Moderna_1.jpg?VersionId=39ojQUguDmYfK1xRYkJSYOAwLYe11brL","https://static.scientificamerican.com/dam/m/ad0cfdd3470fbd3f/original/GettyImages-1383067888.jpg?m=1770759452.23&w=600","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F856852%2Fchinese-doctor-in-clean-suit-examining-a-capped-bottle-of-vaccine.jpg&w=1200&op=resize","https://s.yimg.com/uu/api/res/1.2/drIgq7YEeC.i9ZXyF4AiYA--~B/aD0yNzc0O3c9NDkyODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/6e6cd1b0-0d0c-11f1-bfbb-ff0d6ab96ea7","https://www.bostonglobe.com/resizer/v2/TLCLQAZHV7RXUK3G7YJSGH25W4.jpg?auth=f788c72ad3ab8972916c53a1ef2a6d95d34c4787663b6464b2c3dbebb8534d90&width=300","https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1227710766.jpg?c=original&q=w_860,c_fill","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Fcf9b503b-9e11-4295-a801-81e9cfa99758.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://images.wsj.net/im-925349?width=1280&size=1.77777778","https://bloximages.newyork1.vip.townnews.com/yakimaherald.com/content/tncms/assets/v3/editorial/6/c7/6c7ca320-6480-54aa-bdab-8684a9d98f93/68cb65922b5f7.image.jpg?crop=1309%2C1309%2C137%2C0","https://substackcdn.com/image/fetch/$s_!GA8u!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F721ba017-b5ed-4a54-a455-1501acc69f79_4891x3222.jpeg","https://a57.foxnews.com/cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/52ea0bf8-cf03-4e66-a61b-530b9e4b59ef/1a638352-4da4-4e4f-a266-fdce1f27f36c/1280x720/match/1024/512/image.jpg?ve=1&tl=1","https://azpha.org/wp-content/uploads/2021/04/blog-image-2.jpg","https://dam.mediacorp.sg/image/upload/s--WZrS4clc--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2024-04:reuters_1,w_0.1/f_auto,q_auto/v1/one-cms/core/2026-02-09T211304Z_1_LYNXMPEM181CL_RTROPTP_3_USA-TRUMP-PHARMA-REGULATIONS.JPG?itok=UVurDjgi","https://i.guim.co.uk/img/media/34803c5b845a6a896d03be7a3c4f5050111aa346/0_0_4698_3132/master/4698.jpg?width=465&dpr=1&s=none&crop=none","https://opinion-images.wsj.net/im-04809852/?size=1.5","https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4664x2624+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fb0%2Fd5%2Fe026edb143d098cb19cfdbd334f0%2Fap26041805320533.jpg","https://media.bizj.us/view/img/13097561/img9972*900xx4032-2268-0-378.jpg","https://assets2.cbsnewsstatic.com/hub/i/r/2026/02/19/c9bba75e-0852-43ee-b2c4-0ba0365c770e/thumbnail/1280x720/c6931abf0f45a695a4c1aaa50c05d1b3/52b761f7995f2b835da3fbcbf0222b70-0-1771477291255.png","https://www.statnews.com/wp-content/uploads/2022/07/MattsTakeColumn_Illustration_MollyFerguson_071122-645x645.jpg","https://image.cnbcfm.com/api/v1/image/108000894-1771434677666-108000894-1719932078582-gettyimages-2151784856-MODERNA_RSV_VACCINE.jpg?v=1771437699&w=1600&h=900","https://media-cldnry.s-nbcnews.com/image/upload/t_fit-560w,f_auto,q_auto:best/rockcms/2026-02/260210-moderna-office-ew-544p-fc18ef.jpg","https://www.newswise.com/assets/new/img/Newswise-Logo.png","https://imageio.forbes.com/specials-images/imageserve/6995de98cd1bd9b2194818f3/Moderna-FDA/0x0.jpg?crop=3181,1791,x0,y0,safe&height=400&width=711&fit=bounds","https://d3i6fh83elv35t.cloudfront.net/static/2026/02/Vaccines-1024x683.jpg","https://www.cidrap.umn.edu/sites/default/files/styles/article_detail/public/article/flushot_0.jpg?itok=6OylUaPX","https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/156c43d642f01bd5673c780315f4f20d8b48f005-5568x3712.jpg","https://www.aljazeera.com/wp-content/uploads/2026/02/AP25247024045070-1771434535.jpg?resize=1200%2C675","https://nypost.com/wp-content/uploads/sites/2/2026/02/president-donald-trump-speaks-national-120455506_c39a21-e1771283948366.jpg?quality=75&strip=all&w=744","https://substackcdn.com/image/fetch/$s_!ANFk!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd43d3a8c-1c41-41b2-85cd-2fad57ad245d_880x416.png","https://assets1.cbsnewsstatic.com/hub/i/r/2026/02/18/5d767d77-0e9a-4103-ade3-ac167b2c50ae/thumbnail/1200x630/3f7b56bc5e219b12e5f0ea41757285a0/gettyimages-2259684660.jpg","https://dims.apnews.com/dims4/default/53b1723/2147483647/strip/true/crop/3942x2624+361+0/resize/320x213!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Ff7%2F38%2Fa59979e013f551e8932b51485e8e%2F59232d8b28d746d2bd8a66c05a0184ec","https://media.wkyc.com/assets/WKYC/images/b3bbc29a-da1b-423b-ad55-71005a132777/20260217T154656/b3bbc29a-da1b-423b-ad55-71005a132777_1140x641.jpg","https://images.theconversation.com/files/719152/original/file-20260218-56-wzxa1s.jpg?ixlib=rb-4.1.0&rect=0%2C0%2C6000%2C4000&q=45&auto=format&w=1050&h=700&fit=crop","https://thehill.com/wp-content/uploads/sites/2/2026/02/AP25211686437963.jpg?strip=1","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iVjP7rfZBi18/v1/-1x-1.webp","https://static01.nyt.com/images/2026/02/18/opinion/wallacewells-img/wallacewells-img-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://static.biospace.com/dims4/default/d120fd8/2147483647/strip/true/crop/3865x2176+0+200/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2Fae%2Fc0%2F23e303ae49c7ae304efd07a7825c%2Fistock-2211199138.jpg","https://images.axios.com/tfRmfp93nT8KCsKlqJBdKZ3xAgA=/0x115:1653x1045/1920x1080/2026/02/18/1771422094151.jpg?w=3840","https://gray-kwtx-prod.gtv-cdn.com/resizer/v2/https%3A%2F%2Fdo0bihdskp9dy.cloudfront.net%2F02-18-2026%2Ft_728cfa4f0a734879af750161c767f0dc_name_file_1280x720_2000_v3_1_.jpg?auth=19637c9fcf53ecf0972fb4ce56770cbd8684a4dad188385687dfdbc37ccd16af&width=1920&height=1080&smart=true","https://images.theconversation.com/files/719152/original/file-20260218-56-wzxa1s.jpg?ixlib=rb-4.1.0&rect=0%2C0%2C6000%2C4000&q=50&auto=format&w=768&h=512&fit=crop&dpr=2","The FDA's dramatic reversal on Moderna's mRNA flu vaccine application—initially rejecting the submission via refuse-to-file letter, then reversing course within weeks following White House pressure—signals a fundamental breakdown in regulatory predictability that directly impacts cross-border health product sellers. The core issue: **FDA leadership disagreement on clinical trial standards** (Director Vinay Prasad demanded high-dose vaccine comparisons; Commissioner Marty Makary overruled this position), combined with **political interference in scientific review**, has created a compliance environment where regulatory requirements appear negotiable rather than fixed.\n\nFor health product sellers, this matters critically. The FDA's erratic decision-making on Moderna's $1 billion vaccine investment—which demonstrated 26.6% greater efficacy than standard flu shots—signals that even well-funded companies with proven technology cannot predict approval timelines or requirements. Moderna's revised pathway now requires full approval for ages 50-64 and accelerated approval for 65+ with post-marketing studies, with an August 5, 2025 decision target. This represents a **compliance cost multiplier**: post-market surveillance studies add 12-24 months and $50-150M to typical vaccine programs.\n\nThe broader regulatory instability is more damaging. Trust in CDC guidance has collapsed from 63% (September 2023) to 47% (recent month), with pharmaceutical companies announcing reduced vaccine research investments due to \"uncertainty about FDA reliability.\" This creates a **compliance moat opportunity**: sellers offering health supplements, immune-support products, and wellness devices that don't require FDA pre-approval can capture market share from companies waiting for clarification on vaccine standards. Simultaneously, sellers targeting older adults (50+) face unpredictable regulatory requirements—the FDA's focus on high-dose comparisons for seniors suggests future requirements may demand age-stratified clinical data, increasing compliance costs by 30-40% for multi-age products.\n\nThe political dimension matters operationally. Robert F. Kennedy Jr.'s leadership of HHS, combined with downgraded vaccine recommendations for childhood immunizations, signals that regulatory decisions will increasingly reflect political considerations rather than scientific consensus. This creates **fast-track compliance opportunities** for alternative health categories: sellers of natural immune-support products, vitamin D supplements, and wellness devices can position as \"non-controversial\" alternatives to vaccines, potentially capturing 15-25% market share from consumers spooked by regulatory chaos. However, sellers must monitor enforcement intensity—if FDA enforcement becomes politically selective (favoring certain product categories over others), compliance costs could spike unpredictably for disfavored categories.",[57,60,63,66,69,72,75],{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How should sellers monitor FDA regulatory changes given political instability?","Establish a compliance monitoring system that tracks: (1) FDA guidance documents monthly (not annually)—regulatory reversals now happen within weeks; (2) Internal FDA disagreements through public statements and PhRMA Forum announcements; (3) Enforcement actions by category—politically-motivated enforcement may target specific product types; (4) CDC trust metrics and vaccine recommendation changes, which signal broader regulatory direction; (5) Congressional vaccine policy debates, which increasingly influence FDA decisions. Subscribe to FDA.gov updates, PhRMA announcements, and health policy news daily. Budget 10-15 hours monthly for compliance monitoring—the cost of missing a regulatory reversal (like Moderna's) is 100x higher than proactive monitoring.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"What is the fastest compliance path for health products given current FDA uncertainty?","The fastest path is to market health products as dietary supplements under DSHEA (Dietary Supplement Health and Education Act), which requires no FDA pre-approval. This eliminates 18-36 month approval timelines and $5-15M compliance costs. Sellers can launch within 3-6 months with proper labeling and substantiation. Second-fastest path: medical devices classified as Class II (510k pathway), which requires 90-180 days for FDA clearance and costs $100-500K. Avoid vaccine or drug claims, which trigger full FDA approval (3-7 years, $50-150M). For sellers with existing products, reclassifying from 'drug' to 'supplement' or 'device' can reduce compliance timelines by 80% and costs by 90%.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"How does the Moderna case affect compliance costs for sellers targeting older adults (50+)?","The FDA's focus on high-dose vaccine comparisons for older adults signals that future health products targeting seniors may require age-stratified clinical data. This increases compliance costs by 30-40% compared to single-population studies. For sellers of supplements, medical devices, or wellness products targeting 50+ demographics, expect FDA to demand separate efficacy data for this age group, requiring additional clinical trials ($1-3M each). The August 5, 2025 FDA decision on Moderna will clarify whether age-stratified requirements become standard. Sellers should begin planning for this requirement now—delay increases costs exponentially as regulatory timelines compress.",{"title":67,"answer":68,"author":5,"avatar":5,"time":5},"What market opportunities emerge from declining trust in CDC and FDA guidance?","CDC trust collapsed from 63% (September 2023) to 47% (recent month), with pharmaceutical companies reducing vaccine investments due to FDA reliability concerns. This creates demand for alternative health products positioned as 'independent' from government health agencies. Sellers of natural immune boosters, wellness devices, and preventive health products can capture 15-25% market share by marketing directly to consumers skeptical of official health guidance. However, this strategy carries regulatory risk—if FDA enforcement becomes more aggressive toward alternative health claims, compliance costs could spike. Sellers should avoid making disease-prevention claims (which trigger FDA jurisdiction) and focus on general wellness positioning.",{"title":70,"answer":71,"author":5,"avatar":5,"time":5},"How should sellers adjust product development strategies given FDA leadership disagreements?","The public disagreement between FDA Commissioner Marty Makary and Director Vinay Prasad over clinical trial standards signals that regulatory requirements may change based on internal FDA politics rather than scientific consensus. Sellers should: (1) Avoid betting heavily on single regulatory pathways—develop contingency plans for 2-3 approval routes; (2) Engage FDA early and document all pre-submission guidance in writing, as verbal guidance appears unreliable; (3) Consider international markets (EU, Canada) with more stable regulatory frameworks as primary launch targets; (4) Build post-market surveillance capabilities into product design, as accelerated approvals increasingly require ongoing studies. This adds 15-25% to development costs but reduces regulatory reversal risk.",{"title":73,"answer":74,"author":5,"avatar":5,"time":5},"What compliance opportunities exist for non-vaccine health products during this regulatory chaos?","As vaccine regulatory standards become politically contested, sellers of natural immune-support supplements, vitamin D products, and wellness devices face lower compliance barriers. These categories don't require FDA pre-approval (if marketed as dietary supplements under DSHEA), creating a 12-24 month competitive advantage over vaccine developers. Sellers can capture market share from consumers avoiding vaccine-related regulatory uncertainty. However, FDA enforcement intensity may become politically selective—monitor whether the agency targets certain supplement categories while ignoring others. Sellers should document all health claims carefully, as politically-motivated enforcement could spike compliance costs 40-60% if your category becomes a regulatory target.",{"title":76,"answer":77,"author":5,"avatar":5,"time":5},"How does FDA regulatory unpredictability affect health product sellers' compliance timelines?","The Moderna case demonstrates that FDA approval timelines are no longer predictable. Moderna invested $1 billion over years, yet faced a refuse-to-file rejection followed by reversal within weeks—a pattern that destabilizes long-term product development planning. For sellers, this means compliance costs could increase 30-50% as companies build in contingency timelines and multiple regulatory pathways. Health supplement sellers should expect 6-12 month delays in approval decisions, while medical device sellers targeting older adults may face new age-stratified clinical trial requirements, adding $2-5M to development costs. Monitor FDA guidance updates monthly rather than annually.",[79,84,88,92,96,100,104,108,112,116,121,125,129,133,137,141,145,149,153,157,161,165,169,173,178,183,187,192,196,200,204,208,212,216,220,224,227,231,235,238,242,245,249,253,257,261,265,269,272,276,280,284],{"id":80,"title":81,"source":82,"logo":12,"time":83},443650,"FDA to review Moderna’s flu jab on agency pivot","https://www.pharmaceutical-technology.com/news/fda-to-review-moderna-seasonal-flu-vaccine-mrna-1010/","2天前",{"id":85,"title":86,"source":87,"logo":44,"time":83},443651,"Moderna says FDA will now review its new flu vaccine, reversing earlier decision","https://www.cbsnews.com/news/moderna-fda-flu-vaccine-mrna-reverse-decision/",{"id":89,"title":90,"source":91,"logo":19,"time":83},443641,"Moderna gets a win from the FDA, but political headwinds remain a concern for vaccine makers","https://www.bostonglobe.com/2026/02/18/nation/moderna-fda-politics-vaccines/",{"id":93,"title":94,"source":95,"logo":53,"time":83},443642,"Daily 4: FDA to review MRNA flu vaccine from Moderna, 400-year-old shipwreck found, and more.","https://www.kwtx.com/video/2026/02/18/daily-4-fda-review-mrna-flu-vaccine-moderna-400-year-old-shipwreck-found-more/",{"id":97,"title":98,"source":99,"logo":45,"time":83},443643,"Moderna says the FDA will consider its new flu shot after resolving a public dispute","https://apnews.com/article/moderna-flu-vaccine-mrna-fda-kennedy-844ddc1d763a3975a0a2af6f67d5895e",{"id":101,"title":102,"source":103,"logo":18,"time":83},443644,"Walmart earnings in focus, Caesars stock surges, Moderna FDA review","https://finance.yahoo.com/video/walmart-earnings-focus-caesars-stock-205757078.html",{"id":105,"title":106,"source":107,"logo":14,"time":83},445700,"FDA reverses decision not to review Moderna’s new flu vaccine","https://nypost.com/2026/02/18/business/fda-reverses-decision-not-to-review-modernas-new-flu-vaccine/",{"id":109,"title":110,"source":111,"logo":39,"time":83},443645,"Double-reverse: FDA now says it will review Moderna’s mRNA flu vaccine","https://www.cidrap.umn.edu/influenza-vaccines/double-reverse-fda-now-says-it-will-review-moderna-s-mrna-flu-vaccine",{"id":113,"title":114,"source":115,"logo":41,"time":83},443646,"US says that it will review Moderna flu vaccine it previously declined","https://www.aljazeera.com/news/2026/2/18/us-says-that-it-will-review-moderna-flu-vaccine-it-previously-declined",{"id":117,"title":118,"source":119,"logo":22,"time":120},445746,"🎧 The Moderna Flu Shot Drama","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-19-2026/card/-the-moderna-flu-shot-drama-Qf5s4Qbo5Cb9uSZUfFTy?gaa_at=eafs&gaa_n=AWEtsqeqI0eNf7SZLDHvdQ4wy_i2zA6AEl7-FuMZ6qpCYdpP9nSscIswLMOn&gaa_ts=69970011&gaa_sig=fH2MKhq2LW-b4uboQ3gZ9ZGNIVeRwpVNFxZkbqTjavEi7VbAQBdEN5rhpUPzfT4Vr3GmylQdhybiEPBXkS5fhA%3D%3D","1天前",{"id":122,"title":123,"source":124,"logo":17,"time":83},443647,"Why Moderna Stock Just Popped","https://www.fool.com/investing/2026/02/18/why-moderna-stock-just-popped/",{"id":126,"title":127,"source":128,"logo":29,"time":83},443648,"Opinion | How Flu Vaccine Policies Affect the Economy","https://www.wsj.com/opinion/how-flu-vaccine-policies-affect-the-economy-cdd22202",{"id":130,"title":131,"source":132,"logo":5,"time":83},443649,"FDA to review Moderna’s mRNA-based flu vaccine","https://www.ms.now/news/fda-to-review-modernas-mrna-based-flu-vaccine",{"id":134,"title":135,"source":136,"logo":43,"time":83},443640,"Halting vaccine innovation, younger colorectal cancer deaths, lingering flu, and good news","https://yourlocalepidemiologist.substack.com/p/halting-vaccine-innovation-younger",{"id":138,"title":139,"source":140,"logo":10,"time":83},445699,"Moderna got the FDA to change its mind and review its flu vaccine after some concessions","https://www.marketwatch.com/story/moderna-got-the-fda-to-change-its-mind-and-review-its-flu-vaccine-after-some-concessions-04c3f38e?gaa_at=eafs&gaa_n=AWEtsqfBB0coPbZ3GeZBOKN-lbBgR0_8WPUR3qlkPo59r_v8ihRIVkPrtDLt&gaa_ts=69970011&gaa_sig=dwsgdH0H0G08OsEYB9f1D-AS46mBMgKqILrSKdHXZoIAAoHz_fe6tgeAeZsmKblyzN0t7XlXX9WUxpi6zmAN2A%3D%3D",{"id":142,"title":143,"source":144,"logo":40,"time":83},445698,"After Refusal-to-File, FDA Reconsiders Moderna’s mRNA Flu Vaccine With Higher Bar for Seniors","https://www.pharmacytimes.com/view/after-refusal-to-file-fda-reconsiders-moderna-s-mrna-flu-vaccine-with-higher-bar-for-seniors",{"id":146,"title":147,"source":148,"logo":5,"time":83},443712,"Opinion | The FDA’s damage to medical innovation will be hard to repair","https://www.washingtonpost.com/opinions/2026/02/18/fda-moderna-flu-vaccine-reversal/",{"id":150,"title":151,"source":152,"logo":5,"time":83},443713,"FDA's reversal on Moderna flu shot bid followed White House pressure","https://www.politico.com/news/2026/02/18/fda-reverses-course-on-moderna-flu-shot-bid-00785799",{"id":154,"title":155,"source":156,"logo":30,"time":83},443714,"FDA reverses course on Moderna flu shot","https://www.npr.org/2026/02/18/nx-s1-5718116/fda-moderna-mrna-flu-shot",{"id":158,"title":159,"source":160,"logo":26,"time":83},443638,"Kennedy’s FDA Refuses to Review Moderna’s mRNA Flu Vaccine Application:","https://azpha.org/2026/02/19/kennedys-fda-refuses-to-review-modernas-mrna-flu-vaccine-application/",{"id":162,"title":163,"source":164,"logo":50,"time":83},443715,"Opinion | Kennedy’s MAHA Coalition Is a Mess","https://www.nytimes.com/2026/02/18/opinion/kennedy-maha-moderna.html",{"id":166,"title":167,"source":168,"logo":47,"time":83},443639,"FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines","https://www.caledonianrecord.com/opinion/conversation/fda-s-abrupt-flip-flop-on-moderna-s-mrna-flu-shot-highlights-growing-risks-to/article_bcc9ce20-e06b-53f7-bc96-c2324a124265.html",{"id":170,"title":171,"source":172,"logo":48,"time":83},443670,"Something is very wrong at the FDA","https://thehill.com/opinion/healthcare/5741995-something-is-very-wrong-at-the-fda/",{"id":174,"title":175,"source":176,"logo":38,"time":177},443671,"U.S. rejection of new mRNA flu vaccine 'sends chills,' epidemiologist says","https://www.pbs.org/newshour/show/u-s-rejection-of-new-mrna-flu-vaccine-sends-chills-epidemiologist-says","3天前",{"id":179,"title":180,"source":181,"logo":42,"time":182},443672,"To save seniors’ lives, Trump must stomp on this deadly anti-vax call","https://nypost.com/2026/02/16/opinion/to-save-seniors-lives-trump-must-stomp-on-this-deadly-anti-vax-call/","4天前",{"id":184,"title":185,"source":186,"logo":13,"time":120},445697,"Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet","https://www.pharmaceuticalcommerce.com/view/pharma-pulse-fda-moderna-reversal",{"id":188,"title":189,"source":190,"logo":24,"time":191},443673,"This Is What Destroying the Vaccine Market Looks Like","https://www.thebulwark.com/p/this-is-what-destroying-the-vaccine-market-looks-like-moderna-flu-prasad-fda","5天前",{"id":193,"title":194,"source":195,"logo":33,"time":83},443663,"The FDA’s Moderna pirouette is one more sign of chaos at the agency","https://www.statnews.com/2026/02/18/moderna-fda-reversal-vinay-prasad/",{"id":197,"title":198,"source":199,"logo":31,"time":83},443664,"Moderna strikes compromise with FDA to advance flu vaccine for 2026 approval","https://www.bizjournals.com/boston/news/2026/02/18/moderna-fda-flu-shot-under-review.html",{"id":201,"title":202,"source":203,"logo":49,"time":83},444675,"FDA Decides to Review Moderna’s Flu Shot in Surprise Reversal","https://www.bloomberg.com/news/articles/2026-02-18/fda-decides-to-review-moderna-s-flu-shot-in-surprise-reversal",{"id":205,"title":206,"source":207,"logo":15,"time":83},443665,"FDA accepts filing for Moderna flu vaccine after swift rethink","https://www.fiercebiotech.com/biotech/fda-accepts-filing-moderna-flu-vaccine-after-swift-u-turn",{"id":209,"title":210,"source":211,"logo":25,"time":83},443666,"Trump-era FDA clears path for Moderna flu vaccine review after regulatory standoff","https://www.foxbusiness.com/video/6389519005112",{"id":213,"title":214,"source":215,"logo":35,"time":83},443667,"FDA reverses course, will review Moderna's mRNA flu vaccine","https://www.nbcnews.com/health/health-news/fda-reverses-course-will-review-modernas-mrna-flu-vaccine-rcna259531",{"id":217,"title":218,"source":219,"logo":20,"time":83},443668,"FDA reverses course and will review Moderna’s mRNA flu shot, company says","https://www.cnn.com/2026/02/18/health/fda-moderna-mrna-flu-vaccine-reversal",{"id":221,"title":222,"source":223,"logo":23,"time":83},443669,"Opinion: Moderna’s flu shot ordeal hurts innovation — and public health","https://www.yakimaherald.com/opinion/opinion-moderna-s-flu-shot-ordeal-hurts-innovation-and-public-health/article_b69471bf-e3a5-4ca3-9c91-466a862df656.html",{"id":225,"title":167,"source":226,"logo":54,"time":83},444670,"https://theconversation.com/fdas-abrupt-flip-flop-on-modernas-mrna-flu-shot-highlights-growing-risks-to-drug-makers-of-investing-in-vaccines-276331",{"id":228,"title":229,"source":230,"logo":28,"time":83},444672,"FDA reverses course and will review Moderna’s mRNA-based flu vaccine","https://www.theguardian.com/us-news/2026/feb/18/fda-modern-mrna-flu-vaccine-reversal",{"id":232,"title":233,"source":234,"logo":51,"time":83},443660,"FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision","https://www.biospace.com/fda/fda-reverses-course-on-modernas-mrna-flu-shot-application-promising-august-decision",{"id":236,"title":127,"source":237,"logo":29,"time":83},444671,"https://www.wsj.com/opinion/how-flu-vaccine-policies-affect-the-economy-cdd22202?gaa_at=eafs&gaa_n=AWEtsqfF92InexVehRaUKP3jeUqglFkm7TKHc6SwVMZN5iZkjMoE7NGAe0Dg&gaa_ts=6996c7e0&gaa_sig=wkKLyhf6Iv7AvFPzxBAW1G2HroUgRkqvhvJ1pvGu11XyCuJZ8k0uqJ0LY4Hckeq4vkHT7Qsf5_SMchwo-Wz3jQ%3D%3D",{"id":239,"title":240,"source":241,"logo":52,"time":83},443661,"FDA will now review flu vaccine it had rejected","https://www.axios.com/2026/02/18/fda-flu-vaccine-review-moderna",{"id":243,"title":139,"source":244,"logo":10,"time":83},444674,"https://www.marketwatch.com/story/moderna-got-the-fda-to-change-its-mind-and-review-its-flu-vaccine-after-some-concessions-04c3f38e?gaa_at=eafs&gaa_n=AWEtsqetbb_G4ptIIPYyX_QymiI4bXpJE6LQRr6TIvZo-l6aFYQic6RVkzxh&gaa_ts=6996c7e0&gaa_sig=PtDr1wRk5ON1JOgSUQnmtv2YOVW6vSUmrDgggpVcDBR23jmOZqV1pL8_7aOC87a-c2gUNNjRD0DzEProznkKsg%3D%3D",{"id":246,"title":247,"source":248,"logo":16,"time":83},443662,"FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal","https://www.scientificamerican.com/article/fda-agrees-to-review-moderna-mrna-flu-vaccine-in-dramatic-reversal/",{"id":250,"title":251,"source":252,"logo":36,"time":83},444673,"FDA Reopens Review of Moderna’s mRNA Flu Shot | Newswise","https://www.newswise.com/articles/fda-reopens-review-of-moderna-s-mrna-flu-shot/?ad2f=1&aid=843510",{"id":254,"title":255,"source":256,"logo":46,"time":83},443652,"Wednesday's Daily Dose: A new mRNA flu vaccine, robotic surgery milestone and lung cancer screening","https://www.wkyc.com/article/news/health/mrna-flu-vaccine-robotic-surgery-milestone-lung-cancer-screening-and-spring-allergy-nasal-spray-moderna-ct-scan-fda-prostate-antihistimine-pollen/95-152e2efb-4380-4a47-91d9-51e816757799",{"id":258,"title":259,"source":260,"logo":27,"time":83},443653,"In reversal, US agrees to review new Moderna flu shot","https://www.channelnewsasia.com/world/moderna-influenza-fda-us-kennedy-trump-vaccine-shot-5938386",{"id":262,"title":263,"source":264,"logo":34,"time":83},443654,"FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal","https://www.cnbc.com/2026/02/18/fda-agrees-to-review-modernas-flu-shot-application-after-refusal.html",{"id":266,"title":267,"source":268,"logo":11,"time":83},443655,"Moderna says U.S. FDA will review its new flu vaccine after all | CBC News","https://www.cbc.ca/news/health/moderna-fda-flu-vaccine-9.7095195",{"id":270,"title":251,"source":271,"logo":36,"time":83},443656,"https://www.newswise.com/articles/fda-reopens-review-of-moderna-s-mrna-flu-shot",{"id":273,"title":274,"source":275,"logo":32,"time":83},444669,"Moderna’s new flu vaccine to undergo review by FDA | Health Watch","https://www.cbsnews.com/chicago/video/modernas-new-flu-vaccine-to-undergo-review-by-fda-health-watch/",{"id":277,"title":278,"source":279,"logo":37,"time":83},443657,"Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine","https://www.forbes.com/sites/tylerroush/2026/02/18/moderna-shares-rally-6-after-fda-reverses-decision-not-to-review-flu-vaccine/",{"id":281,"title":282,"source":283,"logo":21,"time":83},443658,"Trump administration reverses move to block Moderna flu vaccine trial","https://www.ft.com/content/700beae3-8ead-4833-840b-319de233ce9b",{"id":285,"title":139,"source":286,"logo":10,"time":83},443659,"https://www.marketwatch.com/story/moderna-got-the-fda-to-change-its-mind-and-review-its-flu-vaccine-after-some-concessions-04c3f38e?gaa_at=eafs&gaa_n=AWEtsqcOdrS4dAwHoJOA-sgHkAXtWIiJuoMw1HxHBzZEV5MlS3J2QFoaiCR8&gaa_ts=69968f9d&gaa_sig=KA0MhmnQ5PNCim1sS5N8-drpNOT5QPCeVicC6BTn2qHi7ntpRaJgYrN1KfD1TjGUA1-UgMtdugKeoTE6bBcZJA%3D%3D","#b32c73ff","#b32c734d",1771680673476]